|
||||||||||||||||||||
|
|
| Upcoming Programs | ||||||
|
|
||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||
Overview
Atherothrombosis is the leading cause of death worldwide and the underlying process in the etiology of acute coronary syndrome (ACS), stroke and vascular death. Cardiovascular risk factors such as obesity, the metabolic syndrome, diabetes mellitus, hypertension, smoking and other "lifestyle" risks contribute to this pandemic of atherothrombotic disease. Patients with ACS, stroke/TIA and PAD (peripheral arterial disease), present major challenges to the primary care clinician in terms of managing CV risk factors and prevention of a second event. This lecture will overview current studies and treatment guidelines for PAD, ACS and Stroke and explore the role of primary care in long-term treatment of these patients.
Objectives
Describe 3 clinical conditions in which dual antiplatelet therapy is recommended
Name 5 treatment recommendations for reduction of global CV risk
Faculty
Martin W. Schwarze, DO, FACC
Clinical Professor of Medicine
St. Louis University School of Medicine
St. Louis, MO
F. Wilford Germino, MD, FAHA
Overview
This presentation will address early and aggressive LDL-C management and the clinical challenges of goal attainment. Clinicians will be provided with pathways and knowledge to help them improve their patient outcomes by goal attainment of the healthy lipid profile.
Discussion will be applicable to clinicians' practice including lifestyle changes of diet and exercise, along with pharmacologic treatment options available for lipid management in order to give the appropriate tools to get patients to their true LDL goals.
Objectives
Understand the key tenets of assessing and managing dyslipidemia in clinical practice and the current evidence regarding the safety and efficacy of available LDL-C lowering therapies
Identify at least 2 lipid lowering strategies to initiate and tailor comprehensive management treatment plans for patients with high LDL-C in order to reach and maintain targeted goals
Faculty
Benjamin J. Ansell, MD
Assistant Professor of Internal Medicine
University of California, Los Angeles (UCLA) School of Medicine
Los Angeles, CA
David A. Leaf, MD, MPH
Professor of Medicine
UCLA School of Medicine
Los Angeles, CA
Overview
The diagnosis, treatment, and on-going management of patients with sleep disorders, which affect 21% of the population, are most commonly the responsibility of the primary care clinician. Utilizing effective screening tools, distinguishing primary versus secondary sleep disorders, recognizing comorbid conditions, and developing a treatment strategy based on individual patient factors can all present as challenges. This activity will provide the information and case-based scenarios to maximize outcomes for patients with sleep disorders.
Objectives
Integrate the use of screening tools to differentiate primary versus secondary sleep disorders
Identify the treatment strategies based on individual patient factors and characteristics
Faculty
Joseph A. Lieberman III, MD, MPH
Professor of Family Medicine
Jefferson Medical College
Thomas Jefferson University
Associate Editor, Delaware Medical Journal
Philadelphia, PA
Michael J. Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine
Bronx, NY
Overview
This educational activity will describe and reinforce tools that enable clinicians to efficiently recognize and diagnose migraine that may have been previously undiagnosed and untreated, or who may have lapsed from treatment, and to communicate realistic treatment goals to reach the goal of improved patient outcomes.
Objectives
Identify the symptoms and patterns of headache for accurate assessment of migraine, including associated risks for progression to chronic migraine, and utilize simple screening tools to overcome diagnostic challenges
Create a migraine management strategy tailored to individual patient needs that incorporates a stratified approach to pharmacological and nonpharmacological therapies and communication of realistic treatment goals to help improve patient outcomes
Faculty
Frederick R. Taylor, MD, FAHS
Adjunct Professor of Neurology
University of Minnesota School of Medicine
Director, Park Nicollet Headache Clinic and Research Center
Minneapolis, MN
Susan Hutchinson, MD
Associate Clinical Professor
Department of Family Medicine
University of CA, Irvine Medical Center
Irvine, CA
Overview
Updated American College of Chest Physicians guidelines acknowledge the pace with which medical therapies for pulmonary arterial hypertension (PAH) are evolving. This educational session will address the new guidelines, diagnostic and functional assessment, and options for lifestyle and pharmacologic therapy. The discussion will be applicable to primary care practitioners and provide them with the awareness, information and evidence based therapies used to manage PAH.
Objectives
Differentiate the hemodynamic abnormalities of pulmonary arterial hypertension including its etiology and pathogenesis in order to decrease morbidity and mortality of the patient population at risk
Apply clinical practice guidelines in the early detection and effective management of PAH by selecting appropriate therapeutic interventions to attain therapeutic goals for patients with PAH
Faculty
Harrison W. Farber, MD
Professor of Medicine
Boston University/Boston Medical Center
Boston, MA
Ronald A. Codario, MD, FACP
Clinical Instructor in Medicine
Thomas Jefferson University Hospital
University of Pennsylvania Health System
Philadelphia, PA
Overview
The National Heart Lung Blood Institute (NHLBI) reports that there are 12 million Americans with obstructive sleep apnea (OSA). Despite the prevalence of this common condition, studies show that 80 -90% of people with OSA remain undiagnosed. Patients who suffer silently with undiagnosed OSA face significant quality of life and associated health issues. Identifying patients with OSA can be a challenge in the busy office setting, and requires the clinician to maintain a high level of suspicion based on sometimes subtle patient complaints, physical exam findings, and OSA risk factors. Once diagnosed and treatment is initiated, successful management is the cornerstone to better patient outcomes. As the first medical contact for most patients with OSA primary care clinicians are crucial for both recognition and management of patients with OSA. This educational activity will provide both the science and the skills that can make significant improvements in the lives of patients with OSA.
Objectives
Recognize the signs and symptoms of OSA and utilize simple assessment questions to identify the possibility of OSA
Identify strategies to assess and monitor patient adherence to treatment for OSA
Faculty
Paul P. Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services, Ursinus College
Collegeville, PA
David Neubauer, MD
Assistant Professor, Department of Psychiatry,
Johns Hopkins University School of Medicine
Medical Director, Psychiatry Mobile Treatment Services,
Johns Hopkins Bayview Medical Center
Associate Director, Johns Hopkins Sleep Disorders Center